Zomedica reports 2021 full-year revenue of $4.1M; net loss $18.4M

Zomedica Corp.

Total revenue of $4.1M in 2021, vs $0 in 2020; gross margin 73.9%.
Net loss $18.4M ($0.05 diluted EPS) vs $16.9M ($0.19) in 2020.
PulseVet Q4 revenue $4.0M, up 66% YoY as standalone; TRUFORMA Q4 revenue $73k, up 224% QoQ.
Cash and equivalents $195M at Dec 31, 2021 vs $62M a year earlier.
Expected to launch eACTH assay in Q2 2022; evaluating M&A opportunities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.